Valuation: Nutra Pharma Corp.

Market Cap 716K 636K 595K 539K 1.02M 69.02M 1.03M 7.14M 2.78M 35.21M 2.69M 2.63M 113M P/E 2024
-0.6x
P/E 2025 -0.38x
Enterprise Value 12.04M 10.69M 10M 9.06M 17.12M 1.16B 17.24M 120M 46.72M 592M 45.19M 44.22M 1.9B EV / Sales 2024
27.1x
EV / Sales 2025 31.2x
Free-Float
98.98%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 2001-10-31
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 64 2016-07-26
Director TitleAgeSince
Director/Board Member 68 2009-07-28
Director/Board Member 78 2004-11-04
Director/Board Member 56 2001-10-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%-2.18%+37.13%+105.01% 1,019B
+0.87%-4.54%+35.75%+62.03% 610B
+0.57%+1.66%+16.28%+80.56% 470B
+1.35%-5.25%+59.29%+36.17% 344B
+0.26%+0.14%+21.29%+40.99% 336B
+0.60%-3.09%+10.76%+32.59% 266B
+1.65%-3.78%-6.03%+9.29% 241B
-0.29%-5.13%+36.64%+50.26% 218B
-0.50%-4.97%+26.57%+92.35% 179B
Average +0.65%-3.63%+26.41%+56.58% 409.2B
Weighted average by Cap. +0.84%-3.51%+29.59%+67.14%

Financials

2024 2025
Net sales 392K 348K 326K 295K 558K 37.8M 562K 3.91M 1.52M 19.28M 1.47M 1.44M 62M 385K 342K 320K 290K 548K 37.14M 552K 3.84M 1.5M 18.95M 1.45M 1.42M 60.91M
Net income -1.29M -1.14M -1.07M -968K -1.83M -124M -1.84M -12.83M -4.99M -63.22M -4.83M -4.72M -203M -2.05M -1.82M -1.7M -1.54M -2.91M -197M -2.93M -20.43M -7.95M -101M -7.69M -7.52M -324M
Net Debt 9.91M 8.8M 8.23M 7.46M 14.09M 955M 14.19M 98.86M 38.45M 487M 37.19M 36.39M 1.57B 11.32M 10.05M 9.41M 8.53M 16.1M 1.09B 16.22M 113M 43.94M 557M 42.5M 41.59M 1.79B
Logo Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. RPI-MN is used to treat neurological diseases and autoimmune diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Rheumatoid Arthritis (RA) and Myasthenia Gravis. The RPI-78M is used to treat viral diseases, including HIV/AIDS and Herpes. The Company offers Nyloxin/Nyloxin Extra Strength as its over-the-counter (OTC) pain reliever. It is focused upon marketing homeopathic drugs for the treatment of pain: Nyloxin, Nyloxin Extra Strength Pet Pain, Equine Pain, and Luxury Feet.
Employees
-